IRIS
CHIMENTI, MARIA SOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.115
AS - Asia 7.741
EU - Europa 5.266
SA - Sud America 1.001
AF - Africa 146
OC - Oceania 98
Continente sconosciuto - Info sul continente non disponibili 4
Totale 55.371
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 40.888
SG - Singapore 3.639
CN - Cina 1.630
RU - Federazione Russa 945
HK - Hong Kong 919
IT - Italia 850
BR - Brasile 838
DE - Germania 588
VN - Vietnam 567
FR - Francia 555
IE - Irlanda 506
UA - Ucraina 414
FI - Finlandia 337
GB - Regno Unito 331
JP - Giappone 247
SE - Svezia 171
PL - Polonia 154
KR - Corea 126
CA - Canada 125
IN - India 124
NL - Olanda 104
ID - Indonesia 71
AR - Argentina 66
MX - Messico 59
AU - Australia 55
BE - Belgio 53
ZA - Sudafrica 52
ES - Italia 51
AT - Austria 50
BD - Bangladesh 49
TR - Turchia 47
NZ - Nuova Zelanda 43
TW - Taiwan 43
DK - Danimarca 39
UZ - Uzbekistan 37
IQ - Iraq 35
EC - Ecuador 30
EG - Egitto 30
IR - Iran 29
PK - Pakistan 26
SA - Arabia Saudita 23
AE - Emirati Arabi Uniti 17
CO - Colombia 17
PH - Filippine 16
CH - Svizzera 15
MA - Marocco 15
IL - Israele 14
MY - Malesia 14
RO - Romania 14
GR - Grecia 13
LT - Lituania 13
CL - Cile 12
TH - Thailandia 12
LV - Lettonia 11
VE - Venezuela 11
TN - Tunisia 10
PY - Paraguay 9
AZ - Azerbaigian 8
BG - Bulgaria 8
ET - Etiopia 8
JM - Giamaica 8
KG - Kirghizistan 8
PE - Perù 8
HR - Croazia 7
HU - Ungheria 7
KE - Kenya 7
DO - Repubblica Dominicana 6
SI - Slovenia 6
HN - Honduras 5
KH - Cambogia 5
OM - Oman 5
SV - El Salvador 5
AL - Albania 4
BO - Bolivia 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
JO - Giordania 4
KW - Kuwait 4
KZ - Kazakistan 4
NG - Nigeria 4
NP - Nepal 4
TT - Trinidad e Tobago 4
EU - Europa 3
NI - Nicaragua 3
PA - Panama 3
SN - Senegal 3
UY - Uruguay 3
YE - Yemen 3
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BH - Bahrain 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
LB - Libano 2
LK - Sri Lanka 2
MK - Macedonia 2
NO - Norvegia 2
PT - Portogallo 2
RS - Serbia 2
Totale 55.344
Salva come PNG Salva come JPEG
Città #
Wilmington 10.067
Woodbridge 9.292
Houston 9.135
Singapore 1.911
Fairfield 1.283
Ann Arbor 982
Ashburn 969
Hong Kong 904
San Jose 805
Chandler 799
Seattle 522
Beijing 458
Dallas 451
Cambridge 438
Dublin 432
New York 367
Jacksonville 334
Medford 330
Columbus 295
The Dalles 294
Santa Clara 289
Los Angeles 259
Helsinki 216
Ho Chi Minh City 203
Rome 203
Council Bluffs 200
Tokyo 197
Zhengzhou 159
Moscow 157
Lawrence 155
Lauterbourg 140
Dearborn 132
Hanoi 115
Buffalo 98
Elk Grove Village 98
São Paulo 95
Kraków 94
Milan 79
San Diego 78
Munich 73
Chicago 65
London 63
Redwood City 63
Menlo Park 59
Redondo Beach 56
Nanjing 53
Orem 52
Nuremberg 51
Seoul 51
Boardman 50
Shanghai 49
Warsaw 48
Brussels 47
Guangzhou 43
Amsterdam 42
Tauranga 42
Stockholm 40
Frankfurt am Main 39
Toronto 39
Chaozhou 37
Jakarta 37
Montreal 37
North Bergen 36
Shenzhen 36
Copenhagen 35
Denver 35
Johannesburg 35
Chengdu 33
Atlanta 31
Brooklyn 31
Norwalk 31
Chennai 30
Palo Alto 28
Phoenix 28
Hefei 26
Lappeenranta 26
Suzhou 26
Mülheim 25
San Francisco 25
Belo Horizonte 24
Haiphong 24
Melbourne 24
Rio de Janeiro 23
Taipei 23
Boston 21
Da Nang 21
Falls Church 21
Manchester 20
Mountain View 20
Vienna 19
Brasília 18
Poplar 18
Esslingen am Neckar 17
San Mateo 17
Augusta 16
Chongqing 16
Del Norte 16
Dhaka 16
Florence 16
Mexico City 16
Totale 45.094
Salva come PNG Salva come JPEG
Nome #
Challenges in the treatment of Rheumatoid Arthritis 840
Type I lamellar ichthyosis improved by tazarotene 0.1% gel 578
Efficacy and safety of infliximab in psoriatic patients over the age of 65 546
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases 540
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 536
Complement, infection, and autoimmunity 529
Complement and autoimmunity 528
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 512
Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure 510
Synovial fluid from patients with rheumatoid arthritis modulates monocyte cell-surface phenotype 508
Vasculitides and the Complement System: a Comprehensive Review 500
Autoantibodies in inflammatory arthritis 500
C3 come indicatore di efficacia terapeutica in pazienti con artrite reumatoide in terapia con inibitori del TNFα 496
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? 485
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 480
Apremilast for the treatment of psoriasis. 477
Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis 472
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab 469
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 466
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor 463
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 463
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 457
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors 456
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 456
Complement system in rheumatoid arthritis: evidence of correlation with disease activity but not with anti-citrullinated protein antibodies 454
Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity 454
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 453
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 453
Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients 452
Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. 450
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 448
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review 446
Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α 445
IL-21 in the pathogenesis and treatment of skin diseases 444
Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation 443
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 439
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 438
The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies 438
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: The experience of two Italian integrated Dermatology/Rheumatology outpatient clinics 437
Occurrence of localized scleroderma morphea in a patient with rheumatoid arthritis treated with etanercept 437
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 437
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 436
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 433
The significance of the development of antinuclear antibodies during infliximab treatment 433
Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 430
Auto-reactions, autoimmunity and psoriatic arthritis 430
The autoimmune side of hereditary angioedema: Insights on the pathogenesis 428
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab 426
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors 426
Complement system in psoriatic arthritis: a useful marker and a potential therapeutic target of anti-tnf-alpha treatment 420
Small-medium vessel vasculitides: Is the complement system a potential forgotten target? 420
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 419
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 419
Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis 414
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 410
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways 410
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment 409
Insights on the role of physical activity in patients with rheumatoid arthritis 409
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 409
Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study 409
Nintedanib in Rheumatoid Arthritis–Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation 407
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 407
The interplay between inflammation and metabolism in rheumatoid arthritis 405
Skin reaction associated with chrysotherapy: an unusual case 403
Innate Immune System at the Maternal–Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes 396
The significance the role of anti-tnf-alpha effects on endothelial dysfunction in psoriasic arthritis 389
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy 386
The pathogenic role of the complement system in rheumatoid arthritis and its relationship with TNFα inhibitors 381
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 380
Ultrasound assessment of enthesis thickness in psoriasis and psoriatic arthritis: A cross-sectional study 379
Morphometric analysis of capillaroscopic images during psoriatic arthritis: comparison with rheumatoid artrhitis 378
Small molecule therapy for managing moderate to severe psoriatic arthritis 378
Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab 370
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 369
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 369
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 368
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence 367
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 366
Natural killer and b cells in patients with rheumatoid arthritis and psoriatic arthritis treated with etanercept 363
Histopathology of the skin in rheumatic diseases 362
The complex interplay between rheumatoid arthritis and atopy: Focus on anti-TNFα treatment 358
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 358
Systemic sclerosis: Exploring the potential interplay between thyroid disorders and pregnancy outcome in an Italian cohort 356
Tofacitinib for the treatment of moderate-to-severe psoriasis 350
How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography 349
Effects of abatacept on T-lymphocyte sub-populations and immunoglobulins in patients affected by rheumatoid arthritis 342
Hereditary angioedema and autoimmunity 341
Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors 340
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 340
Treatment of Hailey-Hailey disease with topical calcitriol 338
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 335
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 328
Evidence for the detection of subclinical retinal involvement in systemic Lupus erythematosus and Sjögren syndrome: a potential association with therapies 315
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 314
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. 311
null 287
Interaction between microbiome and host genetics in psoriatic arthritis 286
Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach 272
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 246
Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view 245
Totale 41.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 145.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 145.670
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021325 0 0 0 0 0 0 0 0 0 0 260 65
2021/20221.711 95 197 160 89 50 86 86 87 97 124 173 467
2022/20232.052 210 177 88 256 188 461 171 135 182 42 104 38
2023/20241.071 95 30 36 28 132 272 43 137 58 19 53 168
2024/20255.481 182 1.203 630 310 71 410 283 220 409 457 706 600
2025/202610.729 702 1.101 1.288 1.204 1.084 419 1.284 1.280 1.147 1.037 183 0
Totale 56.389